Efficacy and safety of linezolid in multidrug resistant tuberculosis (MDR-TB)—a report of ten cases
| Autor: | Per Sandven, Oddbjørn Brubakk, Bent von der Lippe |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Adult
Male Microbiology (medical) medicine.medical_specialty Tuberculosis Combination therapy Microbial Sensitivity Tests chemistry.chemical_compound Anti-Infective Agents Internal medicine Acetamides Tuberculosis Multidrug-Resistant medicine Humans Adverse effect Bone Marrow Diseases Oxazolidinones Antibacterial agent business.industry Linezolid Peripheral Nervous System Diseases Anemia Middle Aged medicine.disease Surgery Treatment Outcome Infectious Diseases Peripheral neuropathy chemistry Blood chemistry Sputum Drug Therapy Combination Female medicine.symptom business |
| Zdroj: | Journal of Infection. 52:92-96 |
| ISSN: | 0163-4453 |
| DOI: | 10.1016/j.jinf.2005.04.007 |
| Popis: | Summary Objectives Multidrug resistant tuberculosis (MDR-TB) is an increasing problem in many parts of the world and in Norway the increase has been substantial since 1998. New therapies for MDR-TB have not been introduced since the fluoroquinolones in the 1970s. The cure rate of this disease has been reported to be lower than for non-drug resistant TB, and the use of new experimental drugs in combination therapy is warranted. Methods Ten consecutive patients with culture proven MDR-TB were treated with the novel antibiotic drug linezolid in combination regimens for 6–40 (median 17) weeks and followed up 11–50 (median 24) months after end of treatment. All strains were sensitive to linezolid with MIC Treatment was given as direct observed therapy (DOT) and sputum cultures, blood chemistry and neurologic examination were undertaken on a regular basis. Results Nine patients were cured, one patient with poor adherence to treatment and advanced AIDS died. Seven of 10 patients experienced serious adverse events, which led to withdrawal of linezolid in all seven. Six patients developed peripheral neuropathy and five patients bone marrow depression, blood transfusions were given to three patients and in all five patients bone marrow function normalized after cessation of linezolid. Peripheral neuropathy was not fully reversed in all patients. Conclusion Linezolid seems highly active in combination treatment of MDR-TB. Cultures became negative 10–37 days after the introduction of the drug. However, peripheral neuropathy and bone marrow depression led to linezolid withdrawal in seven patients, and neuropathy may not be fully reversible in all patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect